PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
P/S ratio for PAVmed Inc. (PAVM)
P/S ratio as of 2023: 12.15
According to PAVmed Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.15. At the end of 2022 the company had a P/S ratio of 113.41.
P/S ratio history for PAVmed Inc. from 2014 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 12.15 |
| 2022 | 113.41 |
| 2021 | 381.38 |
| 2020 | 0.00 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 0.00 |